

06-23-06  
IFW

CASE ON/4-32556A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10	
<u>EV727274104US</u> Express Mail Label Number	<u>June 21, 2006</u> Date of Deposit



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF  
MARGARET HAN DUGAN  
INTERNATIONAL APPLICATION NO: PCT/EP03/06848  
FILED: 27 JUNE 2003  
U.S. APPLICATION NO: 10/518,989  
35 USC §371 DATE: 21 JULY 2005  
FOR: COMBINATION COMPRISING A VASCULOSTATIC COMPOUND  
AND AN ALKYLATING AGENT FOR THE TREATMENT OF A  
TUMOR

**MS: Amendment**  
Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:


Applicant believes this paper is being filed before the mailing date of a first Office action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The asterisked references were cited in the International Search Report and since copies of said references were forwarded by the International Bureau, only copies of the non-asterisked references are enclosed.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,


  
\_\_\_\_\_  
Lydia T. McNally  
Attorney for Applicant  
Reg. No. 36,214

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-7898

Date: June 21, 2006

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



ATTY. DOCKET NO.  
ON/4-32556A  
APPLICATION NO.  
10/518,989  
APPLICANT  
MARGARET HAN DUGAN  
FILING DATE  
JULY 21, 2005

Group

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	* 6,258,812 B1	07/10/01	Bold et al.	514	252.03	02/11/98
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	NO
	AM	* WO 02/076926	10/03/02	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AN	* WO 02/090346	11/14/02	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AO	* WO 03/031440	04/17/03	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	* Bocci et al., "Antitumor Activity of SU5416 in Association with Gemcitabine In Vitro and in Mice Bearing MIA PaCa-2 Human Pancreas Adenocarcinoma", <i>Pancreas</i> , Vol. 21, No. 4, p. 432 (2000)..
	AS	* Browder et al., "Antiangiogenic Scheduling of Chemotherapy Improves Efficacy against Experimental Drug-resistant Cancer", <i>Cancer Res</i> , Vol. 60, No. 7, pp. 1878-1886 (2001).
	AT	Chan et al., "Expression of Vascular Endothelial Growth Factor and Its Receptors in the Anaplastic Progression of Astrocytoma, Oligodendroglioma, and Ependymoma", <i>Am J Surg Pathol</i> , Vol. 22, No. 7, pp. 816-826 (1998).

## EXAMINER

## DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
ON/4-32556A  
APPLICATION NO.  
10/518,989  
APPLICANT  
MARGARET HAN DUGAN  
FILING DATE  
JULY 21, 2005

Group

EXAMINER INITIAL

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	DA	Cheng et al., "Suppression of Glioblastoma Angiogenicity and Tumorigenicity by Inhibition of Endogenous Expression of Vascular Endothelial Growth Factor", <i>Proc Natl Acad Sci USA</i> , Vol. 93, No. 16, pp. 8502-8507 (1996).
	DB	Im et al., "Antiangiogenesis Treatment for Gliomas: Transfer of Antisense-Vascular Endothelial Growth Factor Inhibits Tumor Growth <i>In Vivo</i> ", <i>Cancer Res</i> , Vol. 59, No. 4, pp. 895-900 (1999).
	DC	* Kato et al., "Enhanced Suppression of Tumor Growth by Combination of Angiogenesis Inhibitor O-(chloroacetyl-carbamoyl)fumagillo (TNP-470) and Cytotoxic Agents in Mice", <i>Cancer Res</i> , Vol. 54, No. 19, pp. 5143-5147 (1994).
	DD	Kim et al., "Inhibition of Vascular Endothelial Growth Factor-induced Angiogenesis Suppresses Tumour Growth <i>In Vivo</i> ", <i>Nature</i> , Vol. 362, No. 6423, pp. 841-844 (1993).
	DE	* Lin et al., "The Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor PTK787/ZK222584 Inhibits Growth and Migration of Multiple Myeloma Cells in the Bone Marrow Microenvironment", <i>Cancer Res</i> , Vol. 62, No. 17, pp. 5019-5026 (2002).
	DF	* Ma et al., "Pharmacokinetic-mediated Reduction of Temozolomide Tumor Concentrations by the Angiogenesis Inhibitor TNP-470", <i>Cancer Res</i> , Vol. 61, No. 14, pp. 5491-5498 (2001).
	DG	* Mehta et al., "Radiation Therapy Oncology Group. Research Plan 2002-2006. Brain Tumor Committee", <i>Int J Radiat Oncol Biol Phys</i> , Vol. 51, No. 3, Suppl. 2, pp. 11-18 (2001).
	DH	Millauer et al., "Glioblastoma Growth Inhibited <i>In Vivo</i> by a Dominant-negative Flk-1 Mutant", <i>Nature</i> , Vol. 367, No. 6463, pp. 576-579 (1994).
	DI	* Newton, "Novel Chemotherapeutic Agents for the Treatment of Brain Cancer", <i>Expert Opin Investig Drugs</i> , Vol. 9, No. 12, pp. 2815-2829 (2000).
	DJ	Oehring et al., "Vascular Endothelial Growth Factor (VEGF) in Astrocytic Gliomas – A Prognostic Factor?", <i>J Neuro-Oncol</i> , Vol. 45, pp. 117-125 (1999).
	DK	Plate et al., "Vascular Endothelial Growth Factor is a Potential Tumour Angiogenesis Factor in Human Gliomas <i>In Vivo</i> ", <i>Nature</i> , Vol. 359, No. , pp. 845-848 (1992).
	DL	* Rosen, "Angiogenesis Inhibition in Solid Tumors", <i>Cancer J</i> , Vol. 7, Suppl. 3, pp. S120-S128 (2001).
	DM	Takano et al., "Concentration of Vascular Endothelial Growth Factor in the Serum and Tumor Tissue of Brain Tumor Patients", <i>Cancer Res</i> , Vol. 56, No. 9, pp. 2185-2190 (1996).
	DN	* Teicher et al., "Comparison of Several Antiangiogenic Regimens Alone and With Cytotoxic Therapies in the Lewis Lung Carcinoma", <i>Cancer Chemther Pharmacol</i> , Vol. 38, No. 2, pp. 169-177 (1996).
	DO	Weindel, Moringlane, Marme and Weich, "Detection and Quantification of Vascular Endothelial Growth Factor/Vascular Permeability Factor in Brain Tumor Tissue and Cyst Fluid: The Key to Angiogenesis?", <i>Neurosurgery</i> , Vol. 35, No. 3, pp. 439-449 (1994).

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.